ANI Pharmaceuticals Inc. (ANIP)

About ANIP

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The comp…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

970

Website

www.anipharmaceuticals.com/

Fundamentals

1-day range

$72.61$73.93

Market cap

$1.86B

P/E (trailing)

18.72

P/E (forward)

6.98

EPS (trailing)

$4.29

Dividend yield

—

Beta

0.50

Avg. volume

342.2K

Forecasts

8 analyst ratings

ANI Pharmaceuticals Inc. Competitors

Chosen by industry and closest market cap.

• ANIP

  ANI Pharmaceuticals Inc.

  $72.83

  ▼ 0.93%
  Market cap $1.86BP/E 18.72
  $70.15$99.5
• NBTX

  Nanobiotix S.A. American Depositary Shares

  $41.28

  ▼ 8.59%
  Market cap $1.83BP/E —
  $7.02$47.66
• CMPS

  COMPASS Pathways Plc American Depository Shares

  $13.71

  ▼ 6.35%
  Market cap $1.83BP/E —
• BCAX

  Bicara Therapeutics Inc. Common Stock

  $23.42

  ▼ 5.70%
  Market cap $1.81BP/E —
  $10.3$30.99
• OCUL

  Ocular Therapeutix Inc. Common Stock

  $10.36

  ▼ 4.25%
  Market cap $1.92BP/E —
  $6.23$16.44
• SRPT

  Sarepta Therapeutics Inc. Common Stock (DE)

  $20.85

  ▼ 3.43%
  Market cap $1.77BP/E —
• SNDX

  Syndax Pharmaceuticals Inc. Common Stock

  $19.55

  ▼ 3.05%
  Market cap $1.76BP/E —
  $12.99$25.59

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results
  Benzinga · 8/10/2026
• Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119
  Benzinga · 8/10/2026
• Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90
  Benzinga · 8/10/2026
• ANI Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/8/2026
• ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/7/2026
• ANI Pharmaceuticals (NASDAQ:ANIP) Tumbles on Weak Guidance Despite Q2 EPS Beat
  ChartMill · 8/7/2026
• ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B Est
  Benzinga · 8/7/2026
• ANI Pharmaceuticals Q2 Adj. EPS $2.21 Beats $2.05 Estimate, Sales $266.044M Beat $260.128M Estimate
  Benzinga · 8/7/2026

• Nikhil Lalwani · August 25, 2026 · Sale

  5.4K @ $74.3
• Gosebruch Henry O · August 19, 2026 · Grant

  6.7K
• Stephen P. Carey · July 29, 2026 · Sale

  2.9K @ $81.36
• Meredith Cook · July 18, 2026 · Tax Withholding

  2.5K @ $79.2
• Meredith Cook · July 13, 2026 · Sale

  500 @ $81.84
• Stephen P. Carey · July 2, 2026 · Option Exercise

  3.3K @ $49.51
• Stephen P. Carey · July 2, 2026 · Sale

  3.3K @ $86
• Meredith Cook · June 12, 2026 · Sale

  500 @ $82.03
• Thomas Haughey · June 8, 2026 · Sale

  2.0K @ $80.88
• Stephen P. Carey · June 5, 2026 · Option Exercise

  3.3K @ $49.51
• Stephen P. Carey · June 5, 2026 · Sale

  3.3K @ $80
• Renee P. Tannenbaum · May 21, 2026 · Grant

  4.4K
• Thomas Haughey · May 21, 2026 · Grant

  4.4K
• Jeanne Thoma · May 21, 2026 · Grant

  4.4K
• Matthew J. Leonard · May 21, 2026 · Grant

  4.4K

Institutional Ownership

March 31, 2026

Total shares held

23.18M

Total value held

$1.75B

Institutional holders

272